GB0323965D0 - Immunogenic compositions - Google Patents

Immunogenic compositions

Info

Publication number
GB0323965D0
GB0323965D0 GBGB0323965.4A GB0323965A GB0323965D0 GB 0323965 D0 GB0323965 D0 GB 0323965D0 GB 0323965 A GB0323965 A GB 0323965A GB 0323965 D0 GB0323965 D0 GB 0323965D0
Authority
GB
United Kingdom
Prior art keywords
immunogenic compositions
immunogenic
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0323965.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to GBGB0323965.4A priority Critical patent/GB0323965D0/en
Publication of GB0323965D0 publication Critical patent/GB0323965D0/en
Priority to KR1020067009283A priority patent/KR20070054136A/ko
Priority to RU2006111847/13A priority patent/RU2006111847A/ru
Priority to PCT/EP2004/011620 priority patent/WO2005039634A1/en
Priority to CNA2004800363071A priority patent/CN1889977A/zh
Priority to BRPI0415304-9A priority patent/BRPI0415304A/pt
Priority to AU2004283457A priority patent/AU2004283457A1/en
Priority to CA002541695A priority patent/CA2541695A1/en
Priority to JP2006530155A priority patent/JP2007508272A/ja
Priority to US10/575,838 priority patent/US20070212329A1/en
Priority to EP04790465A priority patent/EP1687025A1/en
Priority to IL174544A priority patent/IL174544A0/en
Priority to IS8374A priority patent/IS8374A/is
Priority to CO06034535A priority patent/CO5700790A2/es
Priority to ZA200602950A priority patent/ZA200602950B/xx
Priority to NO20061912A priority patent/NO20061912L/no
Priority to MA29002A priority patent/MA28149A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB0323965.4A 2003-10-13 2003-10-13 Immunogenic compositions Ceased GB0323965D0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
GBGB0323965.4A GB0323965D0 (en) 2003-10-13 2003-10-13 Immunogenic compositions
RU2006111847/13A RU2006111847A (ru) 2003-10-13 2004-10-11 Вакцинные композиции, содержащие интерлейкин 18 и сапониновую адъювантную систему
JP2006530155A JP2007508272A (ja) 2003-10-13 2004-10-11 インターロイキン１８およびサポニンアジュバント系を含むワクチン組成物
EP04790465A EP1687025A1 (en) 2003-10-13 2004-10-11 Vaccine compositions comprising an interleukin 18 and saponin adjuvant system
PCT/EP2004/011620 WO2005039634A1 (en) 2003-10-13 2004-10-11 Vaccine compositions comprising an interleukin 18 and saponin adjuvant system
CNA2004800363071A CN1889977A (zh) 2003-10-13 2004-10-11 含白介素18和皂苷佐剂系统的疫苗组合物
BRPI0415304-9A BRPI0415304A (pt) 2003-10-13 2004-10-11 métodos de aumentar uma resposta imune a um antìgeno em um mamìfero, e de reduzir a severidade de um cáncer em um paciente, preparação combinada, kit farmacêutico, e, usos de um polipeptìdeo de il-18 ou seu fragmento ou variante bioativos, e de uma composição imunogênica
AU2004283457A AU2004283457A1 (en) 2003-10-13 2004-10-11 Vaccine compositions comprising an interleukin 18 and saponin adjuvant system
CA002541695A CA2541695A1 (en) 2003-10-13 2004-10-11 Vaccine compositions comprising an interleukin 18 and saponin adjuvant system
KR1020067009283A KR20070054136A (ko) 2003-10-13 2004-10-11 인터루킨 18 및 사포닌 애주번트 시스템을 포함하는 백신조성물
US10/575,838 US20070212329A1 (en) 2003-10-13 2004-10-11 Vaccine Compositions Comprising An Interleukin 18 And Saponin Adjuvant System
IL174544A IL174544A0 (en) 2003-10-13 2006-03-23 Vaccine compositions comprising an interleukin 18 and saponin adjuvant system
IS8374A IS8374A (is) 2003-10-13 2006-03-27 Bóluefnissamsetningar sem samanstanda af hvítfrumuboða 18 og sapónín ónæmisglæðakerfi
CO06034535A CO5700790A2 (es) 2003-10-13 2006-04-07 Composiciones de vacuna que comprenden una interleucina 18 y sistema de adyuvante de saponina
ZA200602950A ZA200602950B (en) 2003-10-13 2006-04-11 Vaccine compositions comprising an interleukin 18 and saponin adjuvant system
NO20061912A NO20061912L (no) 2003-10-13 2006-04-28 Vaksinesammensetninger omfattende et interleukin 18 og saponin adjuvant system
MA29002A MA28149A1 (fr) 2003-10-13 2006-05-04 Compositions de vaccin comprenant une interleukine 18 et un systeme adjuvant de type saponine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0323965.4A GB0323965D0 (en) 2003-10-13 2003-10-13 Immunogenic compositions

Publications (1)

Publication Number Publication Date
GB0323965D0 true GB0323965D0 (en) 2003-11-19

Family

ID=29559205

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0323965.4A Ceased GB0323965D0 (en) 2003-10-13 2003-10-13 Immunogenic compositions

Country Status (17)

Country Link
US (1) US20070212329A1 (enExample)
EP (1) EP1687025A1 (enExample)
JP (1) JP2007508272A (enExample)
KR (1) KR20070054136A (enExample)
CN (1) CN1889977A (enExample)
AU (1) AU2004283457A1 (enExample)
BR (1) BRPI0415304A (enExample)
CA (1) CA2541695A1 (enExample)
CO (1) CO5700790A2 (enExample)
GB (1) GB0323965D0 (enExample)
IL (1) IL174544A0 (enExample)
IS (1) IS8374A (enExample)
MA (1) MA28149A1 (enExample)
NO (1) NO20061912L (enExample)
RU (1) RU2006111847A (enExample)
WO (1) WO2005039634A1 (enExample)
ZA (1) ZA200602950B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK12942002A3 (sk) * 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
US7727561B2 (en) 2001-08-31 2010-06-01 Pacific Arrow Limited Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
US7524824B2 (en) * 2003-09-04 2009-04-28 Pacific Arrow Limited Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
US7884083B2 (en) * 2002-08-12 2011-02-08 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
US7514412B2 (en) * 2003-10-09 2009-04-07 Pacific Arrow Limited Anticancer biangeloyl saponins
AU2004281707B2 (en) * 2003-10-09 2011-06-09 Pacific Arrow Limited Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
US7488753B2 (en) * 2003-10-09 2009-02-10 Pacific Arrow Limited Composition comprising triterpene saponins and compounds with angeloyl functional group, methods for preparing same and uses thereof
US8614197B2 (en) * 2003-10-09 2013-12-24 Pacific Arrow Limited Anti-tumor compounds with angeloyl groups
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
DE102004022200B4 (de) 2004-05-05 2006-07-20 Actinium Pharmaceuticals, Inc. Radium-Target sowie Verfahren zu seiner Herstellung
US8735558B2 (en) * 2005-02-14 2014-05-27 Pacific Arrow Limited Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof
US9382285B2 (en) 2004-09-07 2016-07-05 Pacific Arrow Limited Methods and compounds for modulating the secretion or expression of adhesion proteins or angiopoietins of cells
US8586719B2 (en) * 2005-04-27 2013-11-19 Pacific Arrow Limited Triterpenes for modulating gene expression and cell membrane, and as antiprotozoal agents
DE102006008023B4 (de) 2006-02-21 2008-05-29 Actinium Pharmaceuticals, Inc. Verfahren zum Reinigen von 225Ac aus bestrahlten 226Ra-Targets
EP2796575B8 (en) 2006-09-08 2020-04-01 Actinium Pharmaceuticals, Inc. Method for the purification of radium from different sources
AU2008226974B2 (en) * 2007-03-09 2013-08-15 Merck Sharp & Dohme Llc Papillomavirus vaccine compositions
ES2588705T3 (es) * 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
CN101969976A (zh) 2008-01-11 2011-02-09 美国政府健康与人类服务部秘书处 针对分枝杆菌的多肽疫苗和接种策略
CA2723918C (en) 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
ES2569907T3 (es) * 2008-06-27 2016-05-13 Zoetis Services Llc Composiciones adyuvantes novedosas
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
US9566323B2 (en) * 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
US9499577B2 (en) 2009-07-16 2016-11-22 Pacific Arrow Limited Natural and synthetic compounds for treating cancer and other diseases
US9434677B2 (en) 2009-07-16 2016-09-06 Pacific Arrow Limited Natural and synthetic compounds for treating cancer and other diseases
US20120277308A1 (en) 2010-07-16 2012-11-01 Pacific Arrow Limited compounds for treating cancer and other diseases
LT2528621T (lt) * 2010-01-27 2016-12-12 Glaxosmithkline Biologicals S.A. Modifikuoti tuberkuliozės antigenai
HRP20181039T1 (hr) * 2010-05-28 2018-08-24 Zoetis Belgium S.A. Cjepiva koja sadrže kolesterol i cpg kao jedine molekule koje nose adjuvans
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
RU2482866C2 (ru) * 2010-10-07 2013-05-27 Общество с ограниченной ответственностью "Аллоферон" Способ лечения папилломавирусных инфекций, реализуемый через индукцию интерлейкина-18
IN2014CN02581A (enExample) 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
GB201205361D0 (en) 2012-03-27 2012-05-09 Univ Nottingham Trent Breast cancer assay
CA2897084C (en) * 2013-01-04 2019-07-16 Cheng Der Tony Yu Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
KR102586707B1 (ko) 2014-10-01 2023-10-11 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항원 및 어쥬번트로서 인터류킨-21을 갖는 백신
US10456459B2 (en) 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
GB201522329D0 (en) * 2015-12-17 2016-02-03 Glaxosmithkline Biolog S A And Inst Nat De La Sante Et De La Rech Medicale Inserm And Université Pie Use of adjuvants for the prevention and/or treatment of autoimmune diseases
WO2018080253A1 (ko) * 2016-10-31 2018-05-03 아이진 주식회사 면역반응 조절물질 및 양이온성 리포좀을 포함하는 면역증강용 조성물 및 이의 용도
CU24534B1 (es) * 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CN107952069A (zh) * 2017-11-24 2018-04-24 长春百克生物科技股份公司 重组疫苗及其应用
EP3669890A1 (en) 2018-12-18 2020-06-24 Croda International PLC Filamentous nanoparticles having vaccine adjuvant effect
TR201907085A2 (tr) 2019-05-10 2020-11-23 Univ Yeditepe Parazi̇tleri̇n ve parazi̇tlerden elde edi̇len ekstraselüler vezi̇külleri̇n kanser tedavi̇si̇nde kullanimi
CN114466659A (zh) * 2019-09-09 2022-05-10 葛兰素史克生物有限公司 免疫治疗组合物
AU2020403296B2 (en) 2019-12-13 2025-03-06 Grand Theravac Life Science (Nanjing) Co., Ltd. Immunostimulatory composition and use thereof
WO2022034555A1 (en) * 2020-08-13 2022-02-17 Janssen Biopharma, Inc. Polynucleotide constructs and uses thereof
CN116568819A (zh) * 2020-12-09 2023-08-08 葛兰素史克生物有限公司 皂苷的修饰

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69313134T2 (de) * 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6355256B1 (en) * 1994-09-30 2002-03-12 Ludwig Institute For Cancer Research Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
AU3827699A (en) * 1998-05-07 1999-11-23 Akzo Nobel N.V. Use of interleukin-18 as vaccine adjuvant
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
DK1187629T3 (da) * 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
AU2001233212A1 (en) * 2000-02-02 2001-08-14 Schering Corporation Mammalian cytokines; receptors; related reagents and methods
SK12942002A3 (sk) * 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia

Also Published As

Publication number Publication date
RU2006111847A (ru) 2007-11-20
EP1687025A1 (en) 2006-08-09
IS8374A (is) 2006-03-27
NO20061912L (no) 2006-06-02
MA28149A1 (fr) 2006-09-01
ZA200602950B (en) 2007-09-26
IL174544A0 (en) 2006-08-01
WO2005039634A1 (en) 2005-05-06
CA2541695A1 (en) 2005-05-06
US20070212329A1 (en) 2007-09-13
BRPI0415304A (pt) 2006-12-05
KR20070054136A (ko) 2007-05-28
CN1889977A (zh) 2007-01-03
JP2007508272A (ja) 2007-04-05
AU2004283457A1 (en) 2005-05-06
CO5700790A2 (es) 2006-11-30

Similar Documents

Publication Publication Date Title
PL374534A1 (en) Immunogenic compositions
PL376950A1 (pl) Immunogenna kompozycja
GB0301554D0 (en) Immunostimulatory compositions
IL174542A0 (en) Immunogenic compositions
GB0329907D0 (en) Compositions
EP1613352A4 (en) MICRO-AGREED COMPOSITIONS
GB0329597D0 (en) Compositions
GB0315021D0 (en) Immunogenic gonococcal compositions
GB0300602D0 (en) Compositions
AU2003250828A8 (en) Immunogenic compositions
GB0324574D0 (en) Novel compositions
GB0328023D0 (en) Novel compositions
GB0316857D0 (en) Compositions
SI1604683T1 (sl) Vakcinski pripravki na gangliozidni osnovi za subkutano dajanje
GB0315757D0 (en) Immunogenic composition
GB0315772D0 (en) Immunogenic composition
GB0315752D0 (en) Immunogenic composition
GB0317371D0 (en) Immunogenic composition
GB0315764D0 (en) Immunogenic composition
GB0315755D0 (en) Immunogenic composition
GB0315768D0 (en) Immunogenic composition
GB0315778D0 (en) Immunogenic composition
GB0315760D0 (en) Immunogenic composition
GB0315762D0 (en) Immunogenic composition
GB0315767D0 (en) Immunogenic composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)